Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26535578 | 1.00 | GPR119 (0.30) | GPR119 | |
| SCHEMBL26535581 | 0.97 | — | — | |
| SCHEMBL30776523 | 0.97 | — | — | |
| SCHEMBL27084039 | 0.95 | — | — | |
| SCHEMBL27084068 | 0.92 | — | — | |
| SCHEMBL26118160 | 0.90 | BTK (0.32) | — | |
| SCHEMBL30587240 | 0.90 | BTK (0.32) | — | |
| SCHEMBL30776543 | 0.90 | — | — | |
| SCHEMBL31278680 | 0.90 | — | — | |
| SCHEMBL26533528 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025072457-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250101043-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-03-27 | — | — | US | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 617/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | GPR119 617/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 543/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 617/4885 |
| US-20250101043-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.